Medicure Gets Successful DSMB Review From Ongoing MEND-CABG Trial

Medicure has received a recommendation to continue its Phase II/III MEND-CABG trial following a meeting of the independent data safety monitoring board (DSMB).

This recommendation is based on their recent review of the safety data in the majority of patients who have completed 30 days of treatment following coronary artery bypass graft (CABG) surgery.

The DSMB is comprised of independent medical experts and was established by Medicure, in coordination with Duke Clinical Research Institute, as part of the company's compliance with good clinical practices guidelines. The DSMB is responsible for monitoring the safety of patients participating in the MEND-CABG study and for reviewing the safety data throughout its duration. To protect the integrity of the clinical trial, the company remains blinded to the data.